20211104 – Transgene – Q3 Financial update EN
Author: alcyon
Management committee
Management committee Chairman and Chief Executive Officer (CEO) VP, Pharmaceutical Operations & Qualified Pharmacist Chief Scientific Officer (CSO) VP Medical Affairs & Chief Medical Officer (CMO) VP, General Counsel & Corporate Secretary Chief Financial Officer (CFO) Human Resources Director Chief Technical Officer (CTO) VP, Chief Business Officer
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
BT-001 oncolytic virus at SITC 2021
Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation
Publications
Publications To consult all our publications, click here
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
Dr. Laurence ZITVOGEL
MD, Independent Director Laurence Zitvogel, MD, is a professor of immunology and biology at Paris University (Université de Paris Saclay). An oncologist and researcher at Institut Gustave Roussy since 1995, she is internationally renowned for her work in anti-tumor immunology; she has led Phase I and Phase II clinical studies in cancer immunotherapy and deciphered… Continue reading Dr. Laurence ZITVOGEL
Sandrine Flory TSGH
Director, represented by Sandrine FLORY TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative… Continue reading Sandrine Flory TSGH
Maya SAID
Independent Director Maya Said has been an independent Director of Transgene since 2017. She brings more than 15 years of international experience in the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at… Continue reading Maya SAID
Alain MÉRIEUX
Honorary Chairman Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide. In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994,… Continue reading Alain MÉRIEUX